Amer Renal Assoc Stock EBITDA
Amer Renal Assoc fundamentals help investors to digest information that contributes to Amer Renal's financial success or failures. It also enables traders to predict the movement of Amer Stock. The fundamental analysis module provides a way to measure Amer Renal's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amer Renal stock.
Amer |
Amer Renal Assoc Company EBITDA Analysis
Amer Renal's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Amer Renal EBITDA | 113.52 M |
Most of Amer Renal's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amer Renal Assoc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Amer Renal Assoc reported earnings before interest,tax, depreciation and amortization of 113.52 M. This is 87.06% lower than that of the Healthcare sector and 67.28% lower than that of the Diagnostics & Research industry. The ebitda for all United States stocks is 97.09% higher than that of the company.
Amer EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amer Renal's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amer Renal could also be used in its relative valuation, which is a method of valuing Amer Renal by comparing valuation metrics of similar companies.Amer Renal is currently under evaluation in ebitda category among related companies.
Amer Fundamentals
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 | |||
| Profit Margin | (1.11) % | |||
| Operating Margin | 9.73 % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 34.54 M | |||
| Shares Owned By Insiders | 9.15 % | |||
| Shares Owned By Institutions | 80.77 % | |||
| Number Of Shares Shorted | 608.63 K | |||
| Price To Earning | 144.04 X | |||
| Price To Book | (20.05) X | |||
| Price To Sales | 0.49 X | |||
| Revenue | 814.1 M | |||
| Gross Profit | 254.5 M | |||
| EBITDA | 113.52 M | |||
| Net Income | (16.86 M) | |||
| Cash And Equivalents | 126.9 M | |||
| Cash Per Share | 3.68 X | |||
| Total Debt | 724.51 M | |||
| Debt To Equity | 3.94 % | |||
| Current Ratio | 1.05 X | |||
| Book Value Per Share | (2.33) X | |||
| Cash Flow From Operations | 174.15 M | |||
| Short Ratio | 3.91 X | |||
| Earnings Per Share | (0.52) X | |||
| Price To Earnings To Growth | 2.41 X | |||
| Number Of Employees | 4.98 K | |||
| Beta | 1.11 | |||
| Market Capitalization | 397.94 M | |||
| Total Asset | 938.28 M | |||
| Retained Earnings | (192.31 M) | |||
| Working Capital | 96.27 M | |||
| Current Asset | 193.75 M | |||
| Current Liabilities | 97.47 M |
Pair Trading with Amer Renal
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amer Renal position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amer Renal will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Xylem could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xylem when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xylem - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xylem Inc to buy it.
The correlation of Xylem is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xylem moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xylem Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xylem can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Amer Stock
If you are still planning to invest in Amer Renal Assoc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Renal's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |